Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brenda Sandburg

New York, NY
Brenda Sandburg is a senior writer who covers legal issues and FDA regulatory policy, with a particular focus on patents, biosimilars, and government investigations. She spent 10 years writing for legal publications between stints at The Pink Sheet and blends these experiences to provide in-depth analysis of events. An aspiring photographer, she enjoys taking photos to accompany news stories.
Advertisement
Set Alert for Articles By Brenda Sandburg

Latest From Brenda Sandburg

Chronic Fatigue Syndrome Research Takes Leap Forward With NIH Funding

Research centers are collaborating on projects to find causes of disease; Ampligen, Rituxan and KPAX-002 are only drugs in clinical trials.

Research and Development Strategies Neurology

Allergan May Rue Mohawk Tribe Deal As Court Invalidates Restasis Patents

District court questions legitimacy of Allergan's patent transfer tactic, saying it 'could spell the end of the PTO's IPR program.'

Intellectual Property Legal Issues

Allergan May Rue Mohawk Tribe Deal As Court Invalidates Restasis Patents

District court questions legitimacy of Allergan's patent transfer tactic, saying it 'could spell the end of the PTO's IPR program.'

Intellectual Property Policy

FDA Expands Opioid Abuse Research, Outreach

US agency signs contracts for more real-world data on abuse; officials also meet with AMA representatives to discuss opioid prescriber education.

BioPharmaceutical Regulation

Avastin Biosimilar Battle: Amgen, Genentech File Dueling Suits

Amgen seeks declaratory judgement that its biosimilar Mvasi does not infringe 27 Genentech patents, has Genentech suit put under seal; Amgen gave 180-day commercial marketing notice on Oct. 6.

Biosimilars Legal Issues

California Enacts Tough Drug Price Reporting Law

Rx manufacturers must notify state purchasers, health care plans and PBMs of price hikes on drugs with a wholesale acquisition cost greater than $40; follows at least five other state laws, including those of Vermont and Nevada.

Pricing Debate Legislation
See All
Advertisement
UsernamePublicRestriction

Register